Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Organovo Reports Q2 2012 Financial Results, Provides Business Update

August 15, 2012

SAN DIEGO, Aug. 15, 2012 /PRNewswire/ — Organovo Holdings, Inc. (OTCQB: ONVO) (“Organovo”) a three-dimensional biology company focused on delivering breakthrough 3-D bioprinting technology, today reported unaudited financial results for the period ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120813/MM55537LOGO)

Organovo is focused on breakthrough 3D bioprinting technology to create tissue on demand for research and medical applications. The company’s NovoGen MMX Bioprinter(()(TM)()) is part of a 3D human tissue generation platform that works across a broad array of tissue and cell types to recapitulate in vivo biology. Organovo’s bioprinting technology has immediate applications in disease research, drug discovery and development, and toxicology testing. In the future, the Company believes that applications of this technology hold the promise to generate tissues for therapeutic uses.

Second quarter 2012 revenues increased approximately 49% above the same period in 2011. Collaborative research revenues for the second quarter increased approximately 81% over the same period of prior year revenues, but were partially offset by a reduction in grant revenues. Loss from Operations for the second quarter was approximately $1,449,700.

Recent Corporate Highlights
On July 17, 2012, Organovo announced the commencement of operations at its new, larger facility in San Diego, California. The new facility has over three times the capacity of Organovo’s previous headquarters and is expected to facilitate the Company’s needs to grow staff and research and development output.

On July 9, 2012, Organovo announced the receipt of two issued patents. The patents consisted of the issuance in the United States of a patent to which the Company owns the exclusive license from the University of Missouri, and the issuance in the United Kingdom of the Company’s first assigned patent.

On July 9, 2012 Organovo announced the appointment of James T. Glover, former CFO of Beckman Coulter and Anadys Pharmaceuticals, to its Board of Directors. Mr. Glover has been affirmed as an independent director by the Organovo Board of Directors, and the Company expects to attract additional independent directors as it grows.

On May 21, 2012, Organovo announced the hiring of Dr. Eric Michael David as Chief Strategy Officer.

On April 25, 2012, Organovo announced the hiring of Michael Renard as its Executive Vice President, Commercial Operations, and the promotion of Dr. Sharon Presnell to Chief Technology Officer.

The Company is performing on current contracts with Pfizer and United Therapeutics. The Company expects to book revenue on both contracts in the second half of 2012.

“Organovo continues to deliver on plan,” stated Keith Murphy, chief executive officer of Organovo. “Our growing team, seasoned leadership, and greater capacity in the new facility all point to a growth in our impactful research and development efforts, which will contribute to growth in long term shareholder value.”

Financial Results
For the second quarter 2012 total revenues of approximately $259,000 were $85,600 or 49% above the approximately $173,300 in revenues for the same period in 2011. Collaborative research revenues for the second quarter of approximately $259,000 increased $115,600 or 81% over the same period of prior year revenues of approximately $143,400. That growth was partially offset by no grant or product revenues in the second quarter 2012, compared to approximately $30,000 of grant revenues in the prior year second quarter.

Operating expenses increased approximately $1,061,600 or 164% in the second quarter 2012 over the second quarter 2011, from approximately $647,000 in 2011 to $1,708,600 in 2012. Most significantly, relative to the same period in the prior year, the Company invested in infrastructure and outside services to support its transition from private ownership to a publicly owned and traded corporation. As expected in such transition, incremental initiatives were established in investor outreach, corporate governance, and SEC financial reporting. Non-payroll related incremental public company expenses incurred in the second quarter 2012 over the second quarter 2011 was approximately $150,000. There were no second quarter 2011 public company expenses. Moreover, the Company invested in building its executive, research, and development staff, increasing second quarter 2012 payroll related expenses by approximately $523,800 or 174% over the second quarter 2011. Second quarter 2012 executive search fees were approximately $24,000, newly established fees to our non-employee board members were approximately $41,300 and additional space was rented to accommodate our growing administrative and research staff at an approximate incremental cost of $25,000 over the period in 2011.

The increase in other expenses for the second quarter 2012 over the second quarter 2011, an increase of approximately $33,876,600, was primarily related to the non-cash transaction costs associated with the warrants issued in our 2012 Private Placement. During the first quarter of 2012 we incurred costs due to the placement agent for the first quarter Private Placement fees of $1,617,629 and reimbursed expenses and legal fees of $166,310. In addition, we issued warrants to purchase 6,099,195 shares of our common stock to the placement agent and warrants to purchase 15,247,987 of our common stock to investors in the Private Placement. The warrants issued to the placement agent and Private Placement investors were determined to be derivative liabilities as a result of the anti-dilution provisions in the warrant agreements that may result in an adjustment to the warrant exercise price. We will revalue the derivative liability on each balance sheet date and will do so until the securities to which the derivatives liabilities relate are exercised or expire. The change in fair value of warrant liabilities for the three months ended June 30, 2012, was approximately $33,937,200. Other expenses for the three months ended June 30, 2011 of approximately $58,900 related to interest recorded on convertible notes payable.

                                                                                     Organovo Holdings Inc.
                                                                              (A development stage company)
                                                                                   Condensed Balance Sheets

                                               June 30, 2012              December 31, 2011
                                               -------------              -----------------
                                                (Unaudited)                   (Audited)
    Assets
    Current Assets
    Cash and cash equivalents                                 $8,469,312                         $339,607
    Inventory                                                    527,246                          291,881
    Deferred financing costs                                           -                          318,843
    Prepaid expenses and other current assets                    204,488                           79,874
                                                                 -------                           ------

    Total current assets                                       9,201,046                        1,030,205
    Fixed Assets - Net                                           323,153                          278,208
    Restricted Cash                                               88,290                                -
    Other Assets                                                  96,923                          100,419
                                                                  ------                          -------

    Total assets                                              $9,709,412                       $1,408,832
                                                              ==========                       ==========

    Liabilities and Stockholders' Deficit
    Current Liabilities
    Accounts payable                                            $259,518                         $657,560
    Accrued expenses                                             406,371                          437,837
    Deferred revenue                                             223,117                          152,500
    Accrued interest payable                                           -                           24,018
    Convertible notes payable, current portion                         -                          703,833
                                                                     ---                          -------

    Total current liabilities                                    889,006                        1,975,748

    Warrant Liabilities                                       80,577,988                        1,266,869
                                                              ----------                        ---------

    Total liabilities                                        $81,466,994                       $3,242,617

    Commitments and Contingencies

    Stockholders' Deficit
    Common stock, $0.001 par value;
     150,000,000 shares authorized, 43,772,483
     and 22,445,254 issued and outstanding at
     June 30, 2012 and December 31, 2011,
     respectively                                                 43,773                           22,445
    Additional paid-in capital                                 7,355,924                        4,835,326
    Deficit accumulated during the development
     stage                                                   (79,157,279)                      (6,691,556)
                                                             -----------                       ----------

    Total stockholders' deficit                              (71,757,582)                      (1,833,785)
                                                             -----------                       ----------

    Total Liabilities and Stockholders'
     Deficit                                                  $9,709,412                       $1,408,832
                                                              ==========                       ==========
                                                                                                                 Organovo Holdings, Inc.
                                                                                                           (A development stage company)
                                                                                            Unaudited Condensed Statements of Operations

                                                   Three Months Ended              Three Months
                                                                                       Ended           Six Months Ended     Six Months Ended    Period from
                                                     June 30, 2012                June 30, 2011          June 30, 2012        June 30, 2011   April 19, 2007
                                                                                                                                                (Inception)
                                                                                                                                                  through
                                                                                                                                               June 30, 2012
                                                                                                                                               -------------
    Revenues
    Product                                                $                 -  $                -  $                    -          $100,000          $223,500
    Collaborations                                                     258,975             143,375                 378,975           217,740         1,142,063
    Grants                                                                   -              30,000                       -            56,924           664,112
                                                                           ---              ------                     ---            ------           -------

    Total Revenues                                                     258,975             173,375                 378,975           374,664         2,029,675
    Cost of product revenue                                                  -                   -                                    50,584           133,607
    Selling, general, and administrative expenses                    1,056,066             335,946               1,957,909           579,440         4,623,946
    Research and development expenses                                  652,568             311,066               1,199,855           709,730         4,398,243
                                                                       -------             -------               ---------           -------         ---------

    Loss from Operations                                            (1,449,659)           (473,637)             (2,778,789)         (965,090)       (7,126,121)
                                                                    ----------            --------              ----------          --------        ----------

    Other Income (Expense)
    Fair value of warrant liabilities in excess of
     proceeds received                                                       -                   -             (19,019,422)                -       (19,019,422)
    Change in fair value of warrant liabilities                    (33,937,175)                  -             (47,442,994)                -       (47,449,563)
    Financing transaction costs in excess of
     proceeds received                                                       -                   -              (2,129,500)                -        (2,129,500)
    Interest expense                                                         -             (58,843)             (1,087,453)         (111,925)       (3,405,895)
    Interest income                                                      1,692                   -                   1,984                 -             3,990
    Other expense                                                            -                   -                  (9,549)           (1,550)          (30,768)
                                                                           ---                 ---                  ------            ------           -------

    Total Other Income (Expense)                                   (33,935,483)            (58,843)            (69,686,934)         (113,475)      (72,031,158)
                                                                   -----------             -------             -----------          --------       -----------

    Net Loss                                                      $(35,385,142)          $(532,480)           $(72,465,723)      $(1,078,565)     $(79,157,279)
                                                                  ------------           ---------            ------------       -----------      ------------

    Net loss per common share - basic and diluted                       $(0.82)             $(0.05)                 $(1.96)           $(0.10)
    Weighted average shares used in computing net
     loss per common share -basic and diluted                       43,029,026          11,546,910              36,974,745        11,175,474
                                                                                                                                                                Organovo Holdings, Inc.
                                                                                                                                                          (A development stage company)
                                                                                                                                           Unaudited Condensed Statements of Cash Flows

                                                                                Six Months Ended               Six Months Ended                             Period from
                                                                                  June 30, 2012                  June 30, 2011                            April 19, 2007
                                                                                                                                                            (Inception)
                                                                                                                                                              through
                                                                                                                                                           June 30, 2012
                                                                                                                                                           -------------
    Cash Flows From Operating Activities
    Net loss                                                                                     $(72,465,723)                  $(1,078,565)                             $(79,157,279)
    Adjustments to reconcile net loss to net cash used in operating activities:
    Amortization of deferred financing costs                                                          318,843                             -                                   438,296
    Depreciation and amortization                                                                      38,728                        32,430                                   195,056
    Amortization of debt discount                                                                     896,167                             -                                 2,083,735
    Interest accrued on convertible notes payable                                                      11,616                       111,925                                   495,392
    Fair value of warrant liabilities in excess of proceeds                                        19,019,422                             -                                19,019,422
    Change in fair value of warrant liabilities                                                    47,442,994                             -                                47,449,563
    Stock-based compensation                                                                           42,642                         1,882                                    59,591
    Warrants issued in connection with exchange agreement                                                   -                             -                                   527,629
    Increase (decrease) in cash resulting from changes in:
    Accounts receivable                                                                                     -                             -                                         -
    Grants receivable                                                                                       -                        59,744                                         -
    Inventory                                                                                        (235,365)                      (93,717)                                 (527,246)
    Prepaid expenses and other assets                                                                (124,614)                      (10,835)                                 (217,620)
    Accounts payable                                                                                 (398,042)                      213,828                                   259,518
    Accrued expenses                                                                                  (31,467)                       28,918                                   406,371
    Deferred revenue                                                                                   70,618                       125,048                                   223,117
                                                                                                       ------                       -------                                   -------

    Net cash used in operating activities                                                          (5,414,181)                     (609,342)                               (8,744,455)
                                                                                                   ----------                      --------                                ----------

    Cash Flows From Investing Activities
    Restricted cash deposits                                                                          (88,290)                            -                                   (88,290)
    Purchases of fixed assets                                                                         (80,177)                       (9,286)                                 (507,000)
    Purchases of intangible assets                                                                          -                       (65,000)                                  (95,000)
                                                                                                          ---                       -------                                   -------

    Net cash used in investing activities                                                            (168,467)                      (74,286)                                 (690,290)
                                                                                                     --------                       -------                                  --------

    Cash Flows From Financing Activities
    Proceeds from issuance of convertible notes payable                                                     -                       298,700                                 4,630,000
    Proceeds from issuance of common stock and warrants                                            13,822,600                             -                                13,822,600
    Proceeds from issuance of related party notes payable                                                   -                       150,000                                   250,000
    Repayment of related party notes payable                                                                -                       (25,000)                                 (250,000)
    Repayment of convertible notes and interest payable                                              (110,247)                            -                                  (110,247)
    Deferred financing costs                                                                                -                        (6,415)                                 (438,296)
                                                                                                          ---                        ------                                  --------

    Net cash provided by financing activities                                                      13,712,353                       417,285                                17,904,057
                                                                                                   ----------                       -------                                ----------

    Net Increase (Decrease) in Cash and Cash Equivalents                                            8,129,705                      (266,343)                                8,469,312
    Cash and Cash Equivalents at Beginning of Period                                                  339,607                       285,308                                         -
                                                                                                      -------                       -------                                       ---

    Cash and Cash Equivalents at End of Period                                                     $8,469,312                       $18,965                                $8,469,312
                                                                                                   ==========                       =======                                ==========

About Organovo Holdings, Inc.
Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The Company’s NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo’s NovoGen MMX Bioprinter was selected as one of the “Best Inventions of 2010″ by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo’s bioprinting technology can also be developed to create surgical tissues direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

SOURCE Organovo Holdings, Inc.


Source: PR Newswire